[go: up one dir, main page]

US20010006983A1 - Multicomponent biological vehicle - Google Patents

Multicomponent biological vehicle Download PDF

Info

Publication number
US20010006983A1
US20010006983A1 US09/301,892 US30189299A US2001006983A1 US 20010006983 A1 US20010006983 A1 US 20010006983A1 US 30189299 A US30189299 A US 30189299A US 2001006983 A1 US2001006983 A1 US 2001006983A1
Authority
US
United States
Prior art keywords
vehicle
biological
extract
maxcell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/301,892
Other versions
US6395311B2 (en
Inventor
Qi Jia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unigen Inc
Original Assignee
Univera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univera Pharmaceuticals Inc filed Critical Univera Pharmaceuticals Inc
Priority to US09/301,892 priority Critical patent/US6395311B2/en
Assigned to UNIVERA PHARMACEUTICALS, INC reassignment UNIVERA PHARMACEUTICALS, INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JIA, QI
Publication of US20010006983A1 publication Critical patent/US20010006983A1/en
Priority to US10/025,364 priority patent/US20020071868A1/en
Assigned to UNIGEN PHARMACEUTICALS, INC. reassignment UNIGEN PHARMACEUTICALS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERA PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of US6395311B2 publication Critical patent/US6395311B2/en
Assigned to UNIGEN, INC. reassignment UNIGEN, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: UNIGEN PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • the present invention relates generally to a vehicle for the delivery of biologically active agents.
  • this invention includes a biological vehicle formulated from a novel combination of plant extracts that can be used for the delivery of a variety of biologically active agents. Also included in this invention are methods for using the vehicle and formulations containing the vehicle.
  • a vehicle is a substance, usually without biological activity, which is used as a medium for the administration of pharmacologic agents.
  • a vehicle should be nonirritating and compatible with common medications. Criteria for vehicle selection include solubility of the active agent in the vehicle and the ability of the vehicle to penetrate physical barriers such as the stratum comeum and the lipid portion of the cell membrane. Consideration must also be given to any interactions between the vehicle and the active agent, the efficiency with which the vehicle releases the incorporated active ingredient, the molecular size and the composition of the vehicle.
  • Traditional vehicles for subcutaneous administration include oils which tend to be irritating.
  • a vehicle will have a synergistic effect, such that the final sum total of the activity in each system is greater than the sum of the components. This is highly desirable in that less of the pharmacologic agent can be used to achieve the same effect, thereby reducing or eliminating any side effects associated with higher dosages.
  • Aloe is an intricate plant which contains many biologically active substances. (Cohen et al. (1992) in Wound Healing/Biochemical and Clinical Aspects, 1st ed. W B Saunders, Philadelphia). Over 300 species of Aloe are known, most of which are indigenous to Africa. Studies have shown that the biologically active substances are located in three separate sections of the aloe leaf—a clear gel fillet located in the center of the leaf, in the leaf rind or cortex of the leaf and in a yellow fluid contained in the pericyclic cells of the vascular bundles, located between the leaf rind and the internal gel fillet, referred to as the latex.
  • Aloe products have been used in dermatological applications for the treatment of burns, sores and other wounds. These uses have stimulated a great deal of research in identifying compounds from Aloe plants that have clinical activity, especially anti-inflammatory activity.
  • a great deal of research in identifying compounds from Aloe plants that have clinical activity, especially anti-inflammatory activity. See, e.g., Grindlay and Reynolds (1986) J. of Ethnopharmacology 16:117-151; Hart et al. (1988) J. of Ethnopharmacology 23:61-71).
  • As a result of these studies there have been numerous reports of Aloe compounds having diverse biological activities, including anti-tumor activity, anti-gastric ulcer, anti-diabetic, anti-tyrosinase activity, (see, e.g., Yagi et al. (1977) Z. Naturforsch 32c:731-734), and antioxidant activity (International Application Ser. No. PCT/US95/07404).
  • Aloe vera a term used to describe the extract obtained from processing the entire leaf, isolated from the Aloe vera species of Aloe can be used as a vehicle for delivering the corticosteroid, hydrocortisone, administered both topically and subcutaneously to the site of inflammation.
  • Davis et al. studied the topical and systemic anti-inflammatory activity of Aloe vera alone and in combination with hydrocortisone acetate. This study revealed that Aloe vera contributed in an additive way to the activity of the steroid, suggesting that Aloe vera may be useful as a biological vehicle for hydrocortisone.
  • Aloe vera assists in the penetration of hydrocortisone through the stratum corneum.
  • Davis has also shown that Aloe vera can be used as a biological vehicle for the delivery of the estrogenic hormones, estrogen and ⁇ -estradiol and androgenic hormone, testosterone propionate.
  • U.S. application Ser. No. 08/662,654 filed Jun. 13, 1996, entitled, “Method of Using Aloe Vera as a Biological Vehicle,” now issued as U.S. Pat. No. 5,708,038, which is incorporated herein by reference in its entirety).
  • Aloe vera contains many hydrophilic compounds, such as enzymes, amino acids and carbohydrates, as well as, hydrophobic compounds, such as vitamins and sterols, Davis et al. postulate that pharmacologic agents of both solubilities can be placed in Aloe vera and carried through the epidermal barrier. (Davis et al. (1991) JAPMA 81:1).
  • the present invention includes a novel biological vehicle that can be used for the delivery of a variety of biologically active agents.
  • the vehicle called MaxcellTM, is comprised of Aloe polysaccharide fraction Immuno-10 (see U.S. patent application Ser. No. 09/169,449, filed Oct. 9, 1998, entitled “Process for the Preparation of Immunomodulatory Polysaccharides from Aloe,” which is incorporated herein by reference in its entirety), aqueous extract of Ziziphus jujuba fruits, hydrophilic solvent extract of Glycyrrhiza uralensis rhizome, organic solvent extract of Piper nigrum or Piper longum , and calcium inorganic and/or organic salts.
  • MaxcellTM combine to facilitate the harmony between biologically active agents and targeted cells and organs by guiding the biological active agents to their sites of action; by preventing the clearance of the agents from blood; and by protecting cells against harsh properties of biological active agents.
  • the biological vehicle functions as a bioadhesive polymer that selectively binds to the active ingredients thereby forming a complex; the complex thus formed then selectively binds to mannose-6-phosphate receptors on the cell membrane. This serves to promote efficient delivery of the active ingredients to the target cells.
  • the biological vehicle of this invention can be used to deliver a variety of biologically active agents including, but not limited to nutrients and dietary supplements, such as essential minerals like iron, chromium, selenium, zinc, copper, magnesium, manganese, calcium; vitamins such as vitamins A, E, K and D, and vitamins B1, B2, B6 and B12; essential amino acids and derivatives thereof such as arginine, lysine, leucine, phenylalanine, taurine, and N, N-dimethyl glycine; anti-oxidants such as like bioflavonoids, polyphenols, beta-carotene, curcumine, catechins, anthocyanidins; hormones such as melatonin; single plant extracts such as like Echinacea, garlic, Gingko biloba, Goldenseal, Saw palmetto, Ginseng (Panex, Siberian, & American), Cat's claw Astragalus, St John's Wort; and combinations of the above nutrients and dietary supplements,
  • MaxcellTM not only function as a classical delivery system to target bioavailability, but also emphasize the response from the targeted living cells through renewal, enhancement and protection functions. Additionally, the components of MaxcellTM also combine to produce synergistic effects. Also included in the invention is a method for preparing the vehicle, methods for using the vehicle and nutritional supplement formulations containing the vehicle.
  • FIG. 1 illustrates the ability of MaxcellTM and Immuno-10 to stimulate kidney cell renewal (%) as a function of dosage in ⁇ g/mL.
  • FIG. 2 illustrates the ability of MaxcellTM to protect the liver cells of mice against damage caused by high dosage of CCl 4 .
  • FIG. 3 illustrates the ability of Immuno-10 and MaxcellTM to protect cells against UV-B damage. Both Immuno-10 and MaxcellTM provide 18% to 31% protection of cells against UV-B damage.
  • FIG. 4 illustrates Coenzyme Q-10 bioavailability enhancement by MaxcellTM. This figure depicts the increase of rat serum Q-10 level (%) as a function of time.
  • FIG. 5 illustrates Coenzyme Q-10 bioavailability enhancement by MaxcellTM. This figure depicts the rat serum Q-10 concentration ( ⁇ g/mL) increase as a function of time.
  • FIG. 6 illustrates graphically Coenzyme Q-10 bioavailability enhancement by MaxcellTM. This figure depicts the rat serum Q-10 concentration ( ⁇ g/mL) increase as a function of time for Q-10 only ( ⁇ ), Q-10 in combination with Immuno-10 ( ⁇ ) and Q-10 in combination with MaxcellTM ( ⁇ ).
  • FIG. 7 illustrates graphically the combined effect of MaxcellTM and the Super Immune formulation on the stimulation of TNF- ⁇ release from mouse peritoneal macrophages. This figure depicts the release of TNF- ⁇ as a function of dosage.
  • FIG. 8 illustrates the results of the Bio Energy (BioE) formulation Anti-Fatigue test.
  • the present invention describes a novel biological vehicle that can be used for the delivery of a variety of biologically active agents, including but not limited to nutrients, dietary supplements and other compounds with biological activity.
  • the vehicle called MaxcellTM, is comprised of Aloe polysaccharide fraction Immuno-10, aqueous extract of Ziziphus jujuba fruits, hydrophilic solvent extract of Glycyrrhiza uralensis rhizome, organic solvent extract of Piper nigrum or Piper longum , and calcium inorganic and/or organic salts.
  • MaxcellTM combine to: enhance the therapeutic effects of the biologically active agents, enhance intracellular communication and response to biologically active agents, facilitate the transport of biologically active agents into the blood stream following ingestion, bind to and protect biologically active agents, guide the agents to their sites of action and prevent the clearance of the biologically active agents.
  • the biological vehicle can be used to deliver a variety of biologically active agents, including but not limited to nutrients and dietary supplements, such as essential minerals like iron, chromium, selenium, zinc, copper, magnesium, manganese, calcium; vitamins such as vitamins A, E, K and D and vitamins B1, B2, B6 and B12; essential amino acids and derivatives thereof such as arginine, lysine, leucine, phenylalanine, taurine, and N,N-dimethyl glycine; anti-oxidants such as like bioflavonoids, polyphenols, beta-carotene, curcumine, catechins, anthocyanidins; hormones such as melatonin; single plant extracts such as like Echinacea, garlic, Gingko biloba, Goldenseal, Saw palmetto, Ginseng (Panex, Siberian, & American), Cat's claw Astragalus, St John's Wort; and combinations of the above nutrients and dietary supplements.
  • MaxcellTM not only function to enhance bioavailability, but also combine to promote cell renewal, stimulate the immune system and confer protection against toxins and the side effects of drugs. Additionally, the components of MaxcellTM also combine to produce synergistic effects.
  • Aloe refers to the genus of South African plants of the Liliaceae family of which the Aloe barbadensis plant is a species.
  • Aloe vera is defined as the dried inner filet of the leaf of various species of the Aloe plant.
  • Aloe vera polysaccharide refers to polysaccharides isolated from the Aloe plant.
  • Aloe vera polysaccharide fraction Immuno-10 also referred to as “Immuno-10,” refers to a complex carbohydrate preparation produced from the inner filet of the leaf of Aloe species. It functions as a bioadhesive polymer by binding to and coordinating the active ingredients; the complex thus formed then selectively binds to receptors on the cell membrane. This serves to promote efficient delivery of the active ingredients to the target cells.
  • Aloe vera polysaccharide fraction Immuno-10 has been shown to prevent the suppression of contact hypersensitivity in mice exposed to ultraviolet B radiation. Immuno-10 also inhibits ultraviolet B irradiation-induced tumor necrosis factor (TNF- ⁇ ) release in a human epidermoid carcinoma cell line and promotes wound-healing and cellular proliferation, particularly in the immune system.
  • TNF- ⁇ ultraviolet B irradiation-induced tumor necrosis factor
  • a “vehicle” refers to a substance which acts as a physical or physiological carrier for biologically active agents, also referred to as pharmacologic agents.
  • a vehicle aids in the penetration of biologically active agents through physical barriers, such as the stratum corneum, gastrointestinal, respiratory, urinary and blood-brain barriers.
  • a “biological vehicle” also enhances the biological activity of the active agent regardless of the agent under consideration.
  • a biological vehicle not only acts as a carrier, but also has an additive or a synergistic effect as it enhances the effects of other pharmacologic agents.
  • the vehicle of the instant invention is comprised of Aloe vera polysaccharide extract (preferably Immuno-10), cAMP, glycyrrhizinate, piperine alkaloids and calcium inorganic or organic salts.
  • biologically active agent also referred to as “pharmacologic agent,” refers to any substance that can cause a physiological effect in a living organism.
  • Biologically active agents may be derived from natural sources, such as extracts from plants and herbs, or they may be synthesized from precursor components in the laboratory. They include nutrients and nutritional supplements, including but not limited to amino acids, amino acid derivatives, vitamins (both water and fat soluble) and minerals, antioxidants, metabolic intermediates, co-enzymes, cofactors, hormones or any other nutritional supplement known in the art.
  • Biologically active agents also include herb and plant extracts, including but not limited to Echinacea, garlic, Gingko biloba, Goldenseal, Saw palmetto, Ginseng, Gotu kola ( Centella asiatica ), Withania, Kava Kava, Astragalus, St John's wort; and compositions which contain combinations of the above nutrients and dietary supplements.
  • Glycyrrhizinate also referred to as “glycyrrhizinic acid” or its salts, including but not limited to its potassium and ammonium salts, is obtained from the rhizome of Glycyrrhiza uralensis and other species from the same genus.
  • the glycyrrhizinic acid/salt content is typically from 5% to 98% in the crude or refined extract.
  • the Glycyrrhiza species known as licorice is one of the oldest traditional medicines and is used as a tonic, antiphlogistic, mucolytic, expectorant and analgesic for treatment of gastrointestinal and respiratory disorders.
  • Glycyrrhizinic acid and its salts provide protection against rapid DNA damage and inhibit mutagenicity. They also provide protection against gastric ulcers induced by drugs and have been documented as having protective effects against toxins, viruses, tumors and allergic agents.
  • Piperidine is one of the major piperine alkaloids in the hydrophobic extract.
  • the piperidine content in the crude or refined extract is typically between 5% to 97%.
  • Piperidine has been documented for its enhancement of drug bioavailability. It is believed that this effect is due to an increase in the permeability of intestinal epithelial cells, and also to the inhibition of drug metabolism pathways.
  • Piperine alkaloids are also known to function as appetite stimulants, anti-colic and anti-tussive agents, and can induce resistance against infection.
  • cAMP cyclic adenosine monophosphate
  • Ziziphus jujuba can be found in the largest amounts ever reported in the fruit of Ziziphus jujuba , where it is present at 100 to 1000 ⁇ mol/g.
  • the fruits of Ziziphus jujuba have been utilized in traditional medicine to tonify the spleen, augment energy, nourish the blood and calm the spirit.
  • cAMP is known as being one of the key molecules involved in intracellular signal transduction.
  • cAMP is synthesized in cells in response to stimulation from certain hormones or biologically active agents. It binds to and activates a number of protein kinases, which are responsible for a myriad of cellular changes.
  • cAMP has been implicated in switching the direction of nerve growth cone turning, immunostimulation, modulating leukocyte adhesion, modulating superoxide production in macrophages, modulating lipolysis and modulating tumor necrosis factor.
  • Increased levels of cAMP in cells have been shown to potentiate hormonal response in vitro and in vivo and have been used as a treatment for selective weight control, neurodegenerative conditions, viral infections, allergic diseases, thrombosis, platelet aggregation, cardiovascular disease and high intraocular pressure.
  • Calcium inorganic and organic salts
  • Intracellular calcium is synergistic with cAMP as a second messenger during signal transduction. In this way, calcium is believed to potentiate and enhance cellular response to extracellular signals sent by biologically active agents.
  • a biological vehicle is prepared by combining Aloe vera polysaccharide extract (preferably Immuno-10), isolated from Aloe vera gel, Ziziphus jujuba fruit extract containing cAMP, Glycyrrhiza uralensis rhizome extract containing glycyrrhizinate, Piper nigrum or Piper longum fruit extract containing piperine alkaloids and calcium inorganic or organic salts.
  • the individual components are combined respectively in substantially a 10:35:4:4:22 weight:weight ratio.
  • the corresponding biologically active components are formulated respectively as Immuno-10:cAMP:glycyrrhizinate:piperine alkaloids:calcium in substantially a 2:0.005:6:1:10 weight:weight ratio.
  • the resulting biological vehicle may be administrated orally at approximately 100 to 2500 mg/day. In a preferred embodiment the vehicle is administrated at approximately 750 mg/day.
  • the vehicle may be combined with any number of biological agents in order to supply said biological activities.
  • the vehicle and the active biological agents are combined, with the optional inclusion of pharmaceutically acceptable excipients, in the form of, but not limit to, capsules, tablets, soft gel capsules, time-release capsules and liposomes.
  • the amount of MaxcellTM in the composition is from 1% to 99.7% on a weight basis.
  • the biologically active agents can be nutrients and nutritional supplements, such as amino acids, vitamins and derivatives thereof, minerals, anti-oxidants, metabolic intermediates, co-enzymes and co-factors, hormones and derivatives thereof, or any other nutritional supplements known in the art. It is also possible to combine the biological vehicle with herb and plant extracts, including, but not limited to Echinacea, garlic, Gingko biloba , Goldenseal, Saw palmetto, Ginseng (Panex, Siberian and American), Gotu kola ( Centella asiatica ), Withania, Kava Kava, Astragalus, St John's wort, and compositions which contain combinations of the above nutrients and dietary supplements.
  • herb and plant extracts including, but not limited to Echinacea, garlic, Gingko biloba , Goldenseal, Saw palmetto, Ginseng (Panex, Siberian and American), Gotu kola ( Centella asiatica ), Withania, Kava Kava, Astragalus, St
  • Example 1 describes one example of the preparation of the MaxcellTM vehicle.
  • Example 2 describes the ability of MaxcellTM to promote cell renewal. As can be seen in FIG. 1, at a concentration of 2 mg/mL, MaxcellTM stimulates kidney cell proliferation by 55%. When the Immuno-10 polysaccharide fraction (which is a component of MaxcellTM) is tested alone in the same assay, only moderate stimulation (14% -17%) is observed. Therefore, it can be seen that the other ingredients in MaxcellTM act in concert with the Immuno-10 to promote kidney cell proliferation.
  • Example 3 illustrates the ability of MaxcellTM to protect liver cells from damage caused by CCl 4 The results are set forth in FIG. 2.
  • MaxcellTM vehicle also confers protection against ultraviolet B irradiation upon treated cells (Example 4).
  • TNF- ⁇ By monitoring the amount of TNF- ⁇ released following irradiation (a response to UV-B damage), it has been determined that MaxcellTM provides up to 31% more protection than control solutions (data not shown).
  • FIG. 3 illustrates that Immuno-10 and MaxcellTM provide 18% to 31% protection of cells against UV-B damage, respectively.
  • Example 5 illustrate the Coenzyme Q-10 (Q-10) bioavailability enhancement by MaxcellTM.
  • FIG. 4 illustrates the increase of rat serum Q-10 (%) levels as a function of time
  • FIG. 5 illustrates the rat serum Q-10 concentration ( ⁇ g/mL) increase as a function of time for Q-10 only and Q-10 in combination with MaxcellTM.
  • FIG. 6 depicts the rat serum Q-10 concentration ( ⁇ g/mL) increase as a function of time for Q-10 only ( ⁇ ), Q-10 in combination with Immuno-10 ( ⁇ ) and Q-10 in combination with MaxcellTM ( ⁇ ).
  • Example 6 describes the preparation of three different Maxcell formulations: the Bio Energy formulation, the Super Immune formulation, and the Anti-Stress formulation.
  • Example 7 describes the method used to determine the combined effect of the MaxcellTM vehicle and the Super Immune formulation (Formulation 2, Example 6) on macrophage activation.
  • the results are set forth in FIG. 7, which depicts the release of macrophage TNF- ⁇ measured as a function of dosage. As shown in FIG. 7, at all concentrations tested macrophage TNF- ⁇ release was increased by the MaxcellTM vehicle. This result demonstrates the effectiveness of MaxcellTM as a biological vehicle for the delivery of the Super Immune formulation.
  • Example 8 describes the method used to determine the effect of the Bio Energy formulation (BioE) on stamina and the combined effect of the MaxcellTM vehicle and the Bio Energy formulation (BioE) on stamina. The results are set forth in FIG. 8. As shown in FIG. 8, the Bio Energy formulation increases the stamina of the mice when compared to treatment with saline or glucose. Additionally, when used in combination with MaxcellTM the stamina of the mice is enhanced by virtue of the increase in bioavailability of the Bio Energy formulation.
  • Ziziphus jujuba fruit (purchased from the Pacific Ocean Grocery Store, Denver, Colo.) was dried and crushed in a coffee grinder. The product was then freeze dried at room temperature, then finely ground to a small particle powder with a total weight of 857 g. The powder was soaked in 4.5 L of distilled water for 2 hours at 60° C., then centrifuged at 3,000 rpm for 15 minutes at room temperature. The supernatant was filtered into an Erlenmeyer flask. The remaining plant residue was extracted again in the same manner and the two extract solutions were combined and lyophilized to yield 376.7 g of a yellow powder with a sweet taste.
  • the daily dosage of this formulation (750 mg) provides 100 mg Immuno-10, 350 mg Ziziphus extract, 5 mg piperine extract, 245 mg calcium phosphate and 50 mg of monoammonium glycyrrhizinate (>65% pure).
  • This experiment was performed using BHK-21 Baby Hamster Kidney cell line in DMEM (Dulbecco's modified eagle medium)/2.5-10% FBS with 3000-5000 cells/well. The cells were grown in a 96 well flat-bottom tissue culture treated plate.
  • the MaxCellTM solution was prepared in DMEM/FBS/PGS at concentrations of 8.2 ⁇ g/mL, 24.7 ⁇ g/ml, 74.1 ⁇ g/mL, 222.2 ⁇ g/mL, 666.7 ⁇ g/mL and 2000 ⁇ g/mL.
  • Fibroblast growth factor (FGF) was used as a positive control in DMEM/FBS/PGS at a concentration of 150 ng/mL.
  • DMEM/FBS/PGS 200 ⁇ L of DMEM/FBS/PGS was added to all of the perimeter wells of the 96 well cell culture plate, as an experimental control. All experiments were performed in triplicate for FGF and MaxCellTM (6 doses each)/plate.
  • the BHK cells were diluted to 3000-5000 cells/50 ⁇ L (harvested and counted prior to need) in DMEM/FBS/PGS.
  • the samples were placed in a 37° C. incubator for three days, after which 25 ⁇ L/well of MTT was added to all sample and control wells.
  • the plates were incubated plates for 4.5 additional hours followed by addition of 100 ⁇ L extraction solution in the dark, then placed on a wet paper towel and covered with foil at 37° C. The following day the plates were read on dual wavelength 570-630 nm. The result are set forth in FIG. 1.
  • ICR mice 8 weeks of age, were used in this experiment.
  • the animals received food and water ab libitum. They were administrated MaxCellTM in saline at 200 mg/kg, silymarin in saline at 200 mg/kg, and saline only, intraperitoneally for 4 days.
  • the animals received an intraperitoneal injection of carbon tetrachloride (CCl 4 ) at 20 mg/kg in 0.2 mL to induce liver damage.
  • CCl 4 carbon tetrachloride
  • the animals were euthanized by CO 2 asphyxiation and blood was drawn by cardiac puncture into a heparinized syringe.
  • the serum glutamic oxalacetic and glutamic pyruvic transminases levels were determined as described by Reitman and Frankel (1957) 28:56-63. The result are set forth in FIG. 2.
  • MaxcellTM Three different formulations using the instant biological vehicle (MaxcellTM) were prepared. These formulations should be regarded solely as examples, and are not meant to limit the ways in which MaxcellTM may be used.
  • Formulation 1 Bio Energy Dose: 3 tablets per day Daily Dosage Component Amount Effective Range Ginseng extract (Siberian and/or Panex) 250 mg 10-1,000 mg Co-enzyme Q 10 18 mg 5-250 mg ⁇ -ketoglutaric acid 300 mg 50-1,000 mg Potassium magnesium aspartate 300 mg 50-1,000 mg Chromium polynicotinate 300 ⁇ g 50-1,000 ⁇ g MaxcellTM 750 mg 100-2,500 mg
  • Formulation 2 “Super Immune” Formulation Dose: 3 capsules or tablets daily Daily Dosage Component Amount Effective Range Astragalus extract 500 mg 50-1,500 mg Schisandra extract 300 mg 50-1,500 mg Ganoderma extract 150 mg 50-1,000 mg MaxcellTM 750 mg 100-2,500 mg L-arginine 200 mg 50-1,000 mg
  • the Schisandra extract contains schisandrins and the Ganoderma extract contains ganoderic acid and glucans.
  • Formulation 3 “Anti-Stress” Formulation Tablet or capsule Daily Dosage Dose: 2-3 tablets per day Amount Effective Range Ziziphus jujuba Mill var. spinosa 200 mg 50-600 mg seed extract Gotu kola ( Centella asiatica ) 200 mg 50-600 mg whole plant extract Withania somnifera root extract 300 mg 50-600 mg Piper methylsticum rootstock extract 200 mg 50-500 mg Taurine 200 mg 100-1,000 mg MaxcellTM 250 mg 100-2,500 mg
  • MaxcellTM and the Super immune formulation were tested at 1.95 ⁇ g/mL, 3.91 ⁇ g/mL, 7.81 ⁇ g/mL, 15.63 ⁇ g/mL and 31.25 ⁇ g/mL.
  • the TNF- ⁇ released into the media was determined by ELISA.
  • Lipopolysaccharides (LPS) were used as a positive control. The results are set forth in FIG. 7.
  • mice ICR male mice, 8 weeks of age, were used for this experiment. The animals were fasted 18 hours prior to treatment with the Bio Energy formulation. Water was provided ab libitum. Positive control animals (8 mice) received one oral dose of 600 mg/kg glucose via gavage feeding. Negative control animals (8 mice) received one oral dose of 600 mg/kg saline via gavage feeding. Study animals (10 for each group) received 600 mg/mL of the BioEnergy formulation (prepared as described in Example 6) with MaxCellTM, 600 mg/mL of the BioEnergy formulation without MaxCellTM, and 134 mg/mL of MaxCellTM alone.
  • mice received food and water ab libitum after being dosed. After 60 minutes, a 2 gram weight was glued to the end of the tails of the mice. Individual mice were placed into a tub (50 cm ⁇ 30 cm ⁇ 25 cm) of 20+/ ⁇ 0.5° C. water and allowed to swim until their heads went under water. The time of swim was recorded. The animals were then towel-dried and put into a warmed cage on top of a heating pad, until completely dry. The test results are depicted in FIG. 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention provides a novel vehicle for the delivery of biologically active agents. The vehicle, Maxcell™, is formulated from a novel combination of natural plant extracts and is comprised of Aloe vera polysaccharide fraction Immuno-10, cAMP, piperine, calcium phosphate and glycyrrhizinic acid.

Description

    RELATED APPLICATIONS
  • This application claims priority from U.S. Provisional patent application Ser. No. 60/083,420, filed Apr. 29, 1998, entitled “Multicomponent Biological Vehicle.” [0001]
    • FIELD OF INVENTION
  • The present invention relates generally to a vehicle for the delivery of biologically active agents. In particular this invention includes a biological vehicle formulated from a novel combination of plant extracts that can be used for the delivery of a variety of biologically active agents. Also included in this invention are methods for using the vehicle and formulations containing the vehicle. [0002]
    • BACKGROUND OF THE INVENTION
  • A vehicle is a substance, usually without biological activity, which is used as a medium for the administration of pharmacologic agents. Ideally a vehicle should be nonirritating and compatible with common medications. Criteria for vehicle selection include solubility of the active agent in the vehicle and the ability of the vehicle to penetrate physical barriers such as the stratum comeum and the lipid portion of the cell membrane. Consideration must also be given to any interactions between the vehicle and the active agent, the efficiency with which the vehicle releases the incorporated active ingredient, the molecular size and the composition of the vehicle. Traditional vehicles for subcutaneous administration include oils which tend to be irritating. [0003]
  • Occasionally, a vehicle will have a synergistic effect, such that the final sum total of the activity in each system is greater than the sum of the components. This is highly desirable in that less of the pharmacologic agent can be used to achieve the same effect, thereby reducing or eliminating any side effects associated with higher dosages. [0004]
  • Aloe is an intricate plant which contains many biologically active substances. (Cohen et al. (1992) in [0005] Wound Healing/Biochemical and Clinical Aspects, 1st ed. W B Saunders, Philadelphia). Over 300 species of Aloe are known, most of which are indigenous to Africa. Studies have shown that the biologically active substances are located in three separate sections of the aloe leaf—a clear gel fillet located in the center of the leaf, in the leaf rind or cortex of the leaf and in a yellow fluid contained in the pericyclic cells of the vascular bundles, located between the leaf rind and the internal gel fillet, referred to as the latex. Historically, Aloe products have been used in dermatological applications for the treatment of burns, sores and other wounds. These uses have stimulated a great deal of research in identifying compounds from Aloe plants that have clinical activity, especially anti-inflammatory activity. (See, e.g., Grindlay and Reynolds (1986) J. of Ethnopharmacology 16:117-151; Hart et al. (1988) J. of Ethnopharmacology 23:61-71). As a result of these studies there have been numerous reports of Aloe compounds having diverse biological activities, including anti-tumor activity, anti-gastric ulcer, anti-diabetic, anti-tyrosinase activity, (see, e.g., Yagi et al. (1977) Z. Naturforsch 32c:731-734), and antioxidant activity (International Application Ser. No. PCT/US95/07404).
  • Recent research has also shown that Aloe vera, a term used to describe the extract obtained from processing the entire leaf, isolated from the [0006] Aloe vera species of Aloe can be used as a vehicle for delivering the corticosteroid, hydrocortisone, administered both topically and subcutaneously to the site of inflammation. (Davis et al. (1991) JAPMA 81:1). Davis et al. studied the topical and systemic anti-inflammatory activity of Aloe vera alone and in combination with hydrocortisone acetate. This study revealed that Aloe vera contributed in an additive way to the activity of the steroid, suggesting that Aloe vera may be useful as a biological vehicle for hydrocortisone. These studies also revealed that Aloe vera assists in the penetration of hydrocortisone through the stratum corneum. Davis has also shown that Aloe vera can be used as a biological vehicle for the delivery of the estrogenic hormones, estrogen and β-estradiol and androgenic hormone, testosterone propionate. (U.S. application Ser. No. 08/662,654, filed Jun. 13, 1996, entitled, “Method of Using Aloe Vera as a Biological Vehicle,” now issued as U.S. Pat. No. 5,708,038, which is incorporated herein by reference in its entirety). The significance of these findings is that if used in combination with Aloe vera, the dosage of the steroid can be reduced, while maintaining its biological activity, thereby reducing or eliminating any toxic side effects associated with higher dosages. Since Aloe vera contains many hydrophilic compounds, such as enzymes, amino acids and carbohydrates, as well as, hydrophobic compounds, such as vitamins and sterols, Davis et al. postulate that pharmacologic agents of both solubilities can be placed in Aloe vera and carried through the epidermal barrier. (Davis et al. (1991) JAPMA 81:1).
    • SUMMARY OF THE INVENTION
  • The present invention includes a novel biological vehicle that can be used for the delivery of a variety of biologically active agents. The vehicle, called Maxcell™, is comprised of Aloe polysaccharide fraction Immuno-10 (see U.S. patent application Ser. No. 09/169,449, filed Oct. 9, 1998, entitled “Process for the Preparation of Immunomodulatory Polysaccharides from Aloe,” which is incorporated herein by reference in its entirety), aqueous extract of [0007] Ziziphus jujuba fruits, hydrophilic solvent extract of Glycyrrhiza uralensis rhizome, organic solvent extract of Piper nigrum or Piper longum, and calcium inorganic and/or organic salts. The components of Maxcell™ combine to facilitate the harmony between biologically active agents and targeted cells and organs by guiding the biological active agents to their sites of action; by preventing the clearance of the agents from blood; and by protecting cells against harsh properties of biological active agents. The biological vehicle functions as a bioadhesive polymer that selectively binds to the active ingredients thereby forming a complex; the complex thus formed then selectively binds to mannose-6-phosphate receptors on the cell membrane. This serves to promote efficient delivery of the active ingredients to the target cells.
  • The biological vehicle of this invention can be used to deliver a variety of biologically active agents including, but not limited to nutrients and dietary supplements, such as essential minerals like iron, chromium, selenium, zinc, copper, magnesium, manganese, calcium; vitamins such as vitamins A, E, K and D, and vitamins B1, B2, B6 and B12; essential amino acids and derivatives thereof such as arginine, lysine, leucine, phenylalanine, taurine, and N, N-dimethyl glycine; anti-oxidants such as like bioflavonoids, polyphenols, beta-carotene, curcumine, catechins, anthocyanidins; hormones such as melatonin; single plant extracts such as like Echinacea, garlic, Gingko biloba, Goldenseal, Saw palmetto, Ginseng (Panex, Siberian, & American), Cat's claw Astragalus, St John's Wort; and combinations of the above nutrients and dietary supplements. The components of Maxcell™ not only function as a classical delivery system to target bioavailability, but also emphasize the response from the targeted living cells through renewal, enhancement and protection functions. Additionally, the components of Maxcell™ also combine to produce synergistic effects. Also included in the invention is a method for preparing the vehicle, methods for using the vehicle and nutritional supplement formulations containing the vehicle. [0008]
  • It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed. [0009]
    • FIGURES
  • FIG. 1 illustrates the ability of Maxcell™ and Immuno-10 to stimulate kidney cell renewal (%) as a function of dosage in μg/mL. [0010]
  • FIG. 2 illustrates the ability of Maxcell™ to protect the liver cells of mice against damage caused by high dosage of CCl[0011] 4.
  • FIG. 3 illustrates the ability of Immuno-10 and Maxcell™ to protect cells against UV-B damage. Both Immuno-10 and Maxcell™ provide 18% to 31% protection of cells against UV-B damage. [0012]
  • FIG. 4 illustrates Coenzyme Q-10 bioavailability enhancement by Maxcell™. This figure depicts the increase of rat serum Q-10 level (%) as a function of time. [0013]
  • FIG. 5 illustrates Coenzyme Q-10 bioavailability enhancement by Maxcell™. This figure depicts the rat serum Q-10 concentration (μg/mL) increase as a function of time. [0014]
  • FIG. 6 illustrates graphically Coenzyme Q-10 bioavailability enhancement by Maxcell™. This figure depicts the rat serum Q-10 concentration (μg/mL) increase as a function of time for Q-10 only (♦), Q-10 in combination with Immuno-10 (▪) and Q-10 in combination with Maxcell™ (Δ). [0015]
  • FIG. 7 illustrates graphically the combined effect of Maxcell™ and the Super Immune formulation on the stimulation of TNF-α release from mouse peritoneal macrophages. This figure depicts the release of TNF-α as a function of dosage. [0016]
  • FIG. 8 illustrates the results of the Bio Energy (BioE) formulation Anti-Fatigue test. [0017]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention describes a novel biological vehicle that can be used for the delivery of a variety of biologically active agents, including but not limited to nutrients, dietary supplements and other compounds with biological activity. The vehicle, called Maxcell™, is comprised of Aloe polysaccharide fraction Immuno-10, aqueous extract of [0018] Ziziphus jujuba fruits, hydrophilic solvent extract of Glycyrrhiza uralensis rhizome, organic solvent extract of Piper nigrum or Piper longum, and calcium inorganic and/or organic salts. The components of Maxcell™ combine to: enhance the therapeutic effects of the biologically active agents, enhance intracellular communication and response to biologically active agents, facilitate the transport of biologically active agents into the blood stream following ingestion, bind to and protect biologically active agents, guide the agents to their sites of action and prevent the clearance of the biologically active agents. The biological vehicle can be used to deliver a variety of biologically active agents, including but not limited to nutrients and dietary supplements, such as essential minerals like iron, chromium, selenium, zinc, copper, magnesium, manganese, calcium; vitamins such as vitamins A, E, K and D and vitamins B1, B2, B6 and B12; essential amino acids and derivatives thereof such as arginine, lysine, leucine, phenylalanine, taurine, and N,N-dimethyl glycine; anti-oxidants such as like bioflavonoids, polyphenols, beta-carotene, curcumine, catechins, anthocyanidins; hormones such as melatonin; single plant extracts such as like Echinacea, garlic, Gingko biloba, Goldenseal, Saw palmetto, Ginseng (Panex, Siberian, & American), Cat's claw Astragalus, St John's Wort; and combinations of the above nutrients and dietary supplements.
  • The components of Maxcell™ not only function to enhance bioavailability, but also combine to promote cell renewal, stimulate the immune system and confer protection against toxins and the side effects of drugs. Additionally, the components of Maxcell™ also combine to produce synergistic effects. [0019]
  • Certain terms used to describe the invention herein are defined as follows. [0020]
  • The term “Aloe” refers to the genus of South African plants of the Liliaceae family of which the [0021] Aloe barbadensis plant is a species.
  • The term “Aloe vera” is defined as the dried inner filet of the leaf of various species of the Aloe plant. [0022]
  • The term “Aloe vera polysaccharide,” refers to polysaccharides isolated from the Aloe plant. [0023]
  • The term “Aloe vera polysaccharide fraction Immuno-10” also referred to as “Immuno-10,” refers to a complex carbohydrate preparation produced from the inner filet of the leaf of Aloe species. It functions as a bioadhesive polymer by binding to and coordinating the active ingredients; the complex thus formed then selectively binds to receptors on the cell membrane. This serves to promote efficient delivery of the active ingredients to the target cells. In addition to drug delivery functions, Aloe vera polysaccharide fraction Immuno-10 has been shown to prevent the suppression of contact hypersensitivity in mice exposed to ultraviolet B radiation. Immuno-10 also inhibits ultraviolet B irradiation-induced tumor necrosis factor (TNF-α) release in a human epidermoid carcinoma cell line and promotes wound-healing and cellular proliferation, particularly in the immune system. [0024]
  • The typical process for the isolation of Aloe vera polysaccharide involves alcohol precipitation from the juice of [0025] Aloe barbadensis. The instant application makes use of a novel and more efficient procedure, described in the co-pending and commonly assigned U.S. patent application Ser. No. 09/169,449, filed Oct. 9, 1998, entitled “Process for the Preparation of Immunomodulatory Polysaccharides from Aloe,” which is incorporated herein by reference in its entirety.
  • A “vehicle” refers to a substance which acts as a physical or physiological carrier for biologically active agents, also referred to as pharmacologic agents. A vehicle aids in the penetration of biologically active agents through physical barriers, such as the stratum corneum, gastrointestinal, respiratory, urinary and blood-brain barriers. A “biological vehicle” also enhances the biological activity of the active agent regardless of the agent under consideration. Thus, a biological vehicle not only acts as a carrier, but also has an additive or a synergistic effect as it enhances the effects of other pharmacologic agents. The vehicle of the instant invention is comprised of Aloe vera polysaccharide extract (preferably Immuno-10), cAMP, glycyrrhizinate, piperine alkaloids and calcium inorganic or organic salts. [0026]
  • The term “biologically active agent,” also referred to as “pharmacologic agent,” refers to any substance that can cause a physiological effect in a living organism. Biologically active agents may be derived from natural sources, such as extracts from plants and herbs, or they may be synthesized from precursor components in the laboratory. They include nutrients and nutritional supplements, including but not limited to amino acids, amino acid derivatives, vitamins (both water and fat soluble) and minerals, antioxidants, metabolic intermediates, co-enzymes, cofactors, hormones or any other nutritional supplement known in the art. Biologically active agents also include herb and plant extracts, including but not limited to Echinacea, garlic, Gingko biloba, Goldenseal, Saw palmetto, Ginseng, Gotu kola ([0027] Centella asiatica), Withania, Kava Kava, Astragalus, St John's wort; and compositions which contain combinations of the above nutrients and dietary supplements.
  • “Glycyrrhizinate” also referred to as “glycyrrhizinic acid” or its salts, including but not limited to its potassium and ammonium salts, is obtained from the rhizome of [0028] Glycyrrhiza uralensis and other species from the same genus. The glycyrrhizinic acid/salt content is typically from 5% to 98% in the crude or refined extract. The Glycyrrhiza species known as licorice, is one of the oldest traditional medicines and is used as a tonic, antiphlogistic, mucolytic, expectorant and analgesic for treatment of gastrointestinal and respiratory disorders. Glycyrrhizinic acid and its salts provide protection against rapid DNA damage and inhibit mutagenicity. They also provide protection against gastric ulcers induced by drugs and have been documented as having protective effects against toxins, viruses, tumors and allergic agents.
  • “Piperine alkaloids” are a mixture of nitrogen containing compounds existing in the fruit of [0029] Piper longum and Piper nigrum, both indigenous to India. These Ayurvedic herbs are well known as stimulant, carminative and tonic agents. Piperidine is one of the major piperine alkaloids in the hydrophobic extract. The piperidine content in the crude or refined extract is typically between 5% to 97%. Piperidine has been documented for its enhancement of drug bioavailability. It is believed that this effect is due to an increase in the permeability of intestinal epithelial cells, and also to the inhibition of drug metabolism pathways. Piperine alkaloids are also known to function as appetite stimulants, anti-colic and anti-tussive agents, and can induce resistance against infection.
  • “cAMP” (cyclic adenosine monophosphate) can be found in the largest amounts ever reported in the fruit of [0030] Ziziphus jujuba, where it is present at 100 to 1000 μmol/g. The fruits of Ziziphus jujuba have been utilized in traditional medicine to tonify the spleen, augment energy, nourish the blood and calm the spirit. cAMP is known as being one of the key molecules involved in intracellular signal transduction. cAMP is synthesized in cells in response to stimulation from certain hormones or biologically active agents. It binds to and activates a number of protein kinases, which are responsible for a myriad of cellular changes. cAMP has been implicated in switching the direction of nerve growth cone turning, immunostimulation, modulating leukocyte adhesion, modulating superoxide production in macrophages, modulating lipolysis and modulating tumor necrosis factor. Increased levels of cAMP in cells have been shown to potentiate hormonal response in vitro and in vivo and have been used as a treatment for selective weight control, neurodegenerative conditions, viral infections, allergic diseases, thrombosis, platelet aggregation, cardiovascular disease and high intraocular pressure. (See Song et al. (1997) Nature 388:275 Laudanna et al. (1997) J. Biol. Chem. 272:24141; Si et al. (1997) 36:1; Wang et al. J. Biol. Chem (1997) 272:5959; Hoffinan et al. (1984 Am. J. Physiol. 274:E772).
  • “Calcium (inorganic and organic salts)” supply calcium as a nutritional supplement and are also believed to augment intracellular stores of calcium. Intracellular calcium is synergistic with cAMP as a second messenger during signal transduction. In this way, calcium is believed to potentiate and enhance cellular response to extracellular signals sent by biologically active agents. [0031]
  • In one embodiment of the instant invention, a biological vehicle is prepared by combining Aloe vera polysaccharide extract (preferably Immuno-10), isolated from [0032] Aloe vera gel, Ziziphus jujuba fruit extract containing cAMP, Glycyrrhiza uralensis rhizome extract containing glycyrrhizinate, Piper nigrum or Piper longum fruit extract containing piperine alkaloids and calcium inorganic or organic salts. In a preferred embodiment the individual components are combined respectively in substantially a 10:35:4:4:22 weight:weight ratio. The corresponding biologically active components are formulated respectively as Immuno-10:cAMP:glycyrrhizinate:piperine alkaloids:calcium in substantially a 2:0.005:6:1:10 weight:weight ratio.
  • The resulting biological vehicle may be administrated orally at approximately 100 to 2500 mg/day. In a preferred embodiment the vehicle is administrated at approximately 750 mg/day. The vehicle may be combined with any number of biological agents in order to supply said biological activities. In preferred embodiments, the vehicle and the active biological agents are combined, with the optional inclusion of pharmaceutically acceptable excipients, in the form of, but not limit to, capsules, tablets, soft gel capsules, time-release capsules and liposomes. In a preferred embodiment the amount of Maxcell™ in the composition is from 1% to 99.7% on a weight basis. [0033]
  • The biologically active agents can be nutrients and nutritional supplements, such as amino acids, vitamins and derivatives thereof, minerals, anti-oxidants, metabolic intermediates, co-enzymes and co-factors, hormones and derivatives thereof, or any other nutritional supplements known in the art. It is also possible to combine the biological vehicle with herb and plant extracts, including, but not limited to Echinacea, garlic, [0034] Gingko biloba, Goldenseal, Saw palmetto, Ginseng (Panex, Siberian and American), Gotu kola (Centella asiatica), Withania, Kava Kava, Astragalus, St John's wort, and compositions which contain combinations of the above nutrients and dietary supplements.
  • Example 1 describes one example of the preparation of the Maxcell™ vehicle. [0035]
  • Example 2 describes the ability of Maxcell™ to promote cell renewal. As can be seen in FIG. 1, at a concentration of 2 mg/mL, Maxcell™ stimulates kidney cell proliferation by 55%. When the Immuno-10 polysaccharide fraction (which is a component of Maxcell™) is tested alone in the same assay, only moderate stimulation (14% -17%) is observed. Therefore, it can be seen that the other ingredients in Maxcell™ act in concert with the Immuno-10 to promote kidney cell proliferation. [0036]
  • Example 3 illustrates the ability of Maxcell™ to protect liver cells from damage caused by CCl[0037] 4 The results are set forth in FIG. 2.
  • The Maxcell™ vehicle also confers protection against ultraviolet B irradiation upon treated cells (Example 4). By monitoring the amount of TNF-α released following irradiation (a response to UV-B damage), it has been determined that Maxcell™ provides up to 31% more protection than control solutions (data not shown). FIG. 3 illustrates that Immuno-10 and Maxcell™ provide 18% to 31% protection of cells against UV-B damage, respectively. [0038]
  • Example 5 (FIGS. [0039] 4-6) illustrate the Coenzyme Q-10 (Q-10) bioavailability enhancement by Maxcell™. FIG. 4 illustrates the increase of rat serum Q-10 (%) levels as a function of time FIG. 5 illustrates the rat serum Q-10 concentration (μg/mL) increase as a function of time for Q-10 only and Q-10 in combination with Maxcell™. FIG. 6 depicts the rat serum Q-10 concentration (μg/mL) increase as a function of time for Q-10 only (♦), Q-10 in combination with Immuno-10 (▪) and Q-10 in combination with Maxcell™ (Δ).
  • Example 6 describes the preparation of three different Maxcell formulations: the Bio Energy formulation, the Super Immune formulation, and the Anti-Stress formulation. [0040]
  • Example 7 describes the method used to determine the combined effect of the Maxcell™ vehicle and the Super Immune formulation ([0041] Formulation 2, Example 6) on macrophage activation. The results are set forth in FIG. 7, which depicts the release of macrophage TNF-α measured as a function of dosage. As shown in FIG. 7, at all concentrations tested macrophage TNF-α release was increased by the Maxcell™ vehicle. This result demonstrates the effectiveness of Maxcell™ as a biological vehicle for the delivery of the Super Immune formulation.
  • Example 8 describes the method used to determine the effect of the Bio Energy formulation (BioE) on stamina and the combined effect of the Maxcell™ vehicle and the Bio Energy formulation (BioE) on stamina. The results are set forth in FIG. 8. As shown in FIG. 8, the Bio Energy formulation increases the stamina of the mice when compared to treatment with saline or glucose. Additionally, when used in combination with Maxcell™ the stamina of the mice is enhanced by virtue of the increase in bioavailability of the Bio Energy formulation. [0042]
  • The following examples are presented for illustrative purposes only and are not intended to limit the scope of the invention. [0043]
    • EXAMPLES Example 1 Preparation of the Maxcell™ Vehicle
  • Extraction of [0044] Ziziphus jujuba fruit. Ziziphus jujuba fruit (purchased from the Pacific Ocean Grocery Store, Denver, Colo.) was dried and crushed in a coffee grinder. The product was then freeze dried at room temperature, then finely ground to a small particle powder with a total weight of 857 g. The powder was soaked in 4.5 L of distilled water for 2 hours at 60° C., then centrifuged at 3,000 rpm for 15 minutes at room temperature. The supernatant was filtered into an Erlenmeyer flask. The remaining plant residue was extracted again in the same manner and the two extract solutions were combined and lyophilized to yield 376.7 g of a yellow powder with a sweet taste.
  • Preparation of Maxcell™. 100 g of Aloe polysaccharide fraction Immuno-10, prepared as described in co-pending and commonly assigned U.S. patent application Ser. No. 09/169,449, filed Oct. 9, 1998, entitled “Process for the Preparation of Immunomodulatory Polysaccharides from Aloe,” which is incorporated herein by reference in its entirety, was combined with 350 g Ziziphus extract, 40 g of solvent extract from [0045] Piper nigrum, 220 g calcium phosphate and 40 g of monoammonium glycyrrhizinate (>65% pure).
  • The daily dosage of this formulation (750 mg) provides 100 mg Immuno-10, 350 mg Ziziphus extract, 5 mg piperine extract, 245 mg calcium phosphate and 50 mg of monoammonium glycyrrhizinate (>65% pure). [0046]
    • Example 2 Stimulation of Cell Proliferation by Maxcell™
  • This experiment was performed using BHK-21 Baby Hamster Kidney cell line in DMEM (Dulbecco's modified eagle medium)/2.5-10% FBS with 3000-5000 cells/well. The cells were grown in a 96 well flat-bottom tissue culture treated plate. The MaxCell™ solution was prepared in DMEM/FBS/PGS at concentrations of 8.2 μg/mL, 24.7 μg/ml, 74.1 μg/mL, 222.2 μg/mL, 666.7 μg/mL and 2000 μg/mL. Fibroblast growth factor (FGF) was used as a positive control in DMEM/FBS/PGS at a concentration of 150 ng/mL. 200 μL of DMEM/FBS/PGS was added to all of the perimeter wells of the 96 well cell culture plate, as an experimental control. All experiments were performed in triplicate for FGF and MaxCell™ (6 doses each)/plate. The BHK cells were diluted to 3000-5000 cells/50 μL (harvested and counted prior to need) in DMEM/FBS/PGS. The samples were placed in a 37° C. incubator for three days, after which 25 μL/well of MTT was added to all sample and control wells. The plates were incubated plates for 4.5 additional hours followed by addition of 100 μL extraction solution in the dark, then placed on a wet paper towel and covered with foil at 37° C. The following day the plates were read on dual wavelength 570-630 nm. The result are set forth in FIG. 1. [0047]
    • Example 3 Protection of Liver cells by MaxCell™
  • ICR mice, 8 weeks of age, were used in this experiment. The animals received food and water ab libitum. They were administrated MaxCell™ in saline at 200 mg/kg, silymarin in saline at 200 mg/kg, and saline only, intraperitoneally for 4 days. After the fourth dose the animals received an intraperitoneal injection of carbon tetrachloride (CCl[0048] 4) at 20 mg/kg in 0.2 mL to induce liver damage. After 24 hours of treatment with CCl4, the animals were euthanized by CO2 asphyxiation and blood was drawn by cardiac puncture into a heparinized syringe. The serum glutamic oxalacetic and glutamic pyruvic transminases levels were determined as described by Reitman and Frankel (1957) 28:56-63. The result are set forth in FIG. 2.
    • Example 4 Effect of MaxCell™ on Immuno-10 Protection against UV Radiation-Induced Local and Systemic Suppression of Inflammatory Responses
  • This experiment was performed as described by Wolf et al. (1993) The Journal of Investigative Dermatology 100:254-259, which is incorporated herein by reference in its entirety. The Immuno-10 was prepared as described in copending U.S. patent application Ser. No. 09/169,449, filed Oct. 9, 1998, entitled “Process for the Preparation of Immunomodulatory Polysaccharides from Aloe.” The dosage of Maxcell™ and Immuno-10 was 0.5 mg/mL. The results are set forth in FIG. 3. [0049]
    • Example 5 Enhancement of the Bioavilability of Coenzyme Q (Q-10) by Maxcell™
  • CD male rats, 8 weeks of age, were used for this experiment. The animals were fasted 18 hours and cannulated. Water was provided ab libitum. Positive control animals (4 rats) received one oral dose of 50 mg/kg Q-10 in 400 μL of soy bean oil. Negative control animals (4 rats) received one oral dose of 50 mg/kg saline. Study animals (2×4 for each group) received one oral dose of 200 mg/mL of MaxCell™ (prepared as described in Example 1) or Immuno-10 (prepared as described in copending U.S. patent application Ser. No. 09/169,449, filed Oct. 9, 1998, entitled “Process for the Preparation of Immunomodulatory Polysaccharides from Aloe”) with 50 mg/kg Q-10 in 400 μL of Soybean oil. Approximately 600 μL of blood was taken at 1, 2, 3, 4, 6, and 8 hours. The blood was analyzed to determine the amount of coenzyme Q in the plasma as described by Kaplan et al. (1995) Physiol. Res. 44:39-45. The results are set forth in FIGS. [0050] 4-6.
    • Example 6 Maxcell™ Formulations
  • Three different formulations using the instant biological vehicle (Maxcell™) were prepared. These formulations should be regarded solely as examples, and are not meant to limit the ways in which Maxcell™ may be used. [0051]
    Formulation 1. Bio Energy
    Dose: 3 tablets per day Daily Dosage
    Component Amount Effective Range
    Ginseng extract (Siberian and/or Panex) 250 mg  10-1,000 mg
    Co-enzyme Q10  18 mg 5-250 mg
    α-ketoglutaric acid 300 mg  50-1,000 mg
    Potassium magnesium aspartate 300 mg  50-1,000 mg
    Chromium polynicotinate 300 μg  50-1,000 μg
    Maxcell™ 750 mg 100-2,500 mg
  • [0052]
    Formulation 2. “Super Immune” Formulation
    Dose: 3 capsules or tablets daily Daily Dosage
    Component Amount Effective Range
    Astragalus extract 500 mg  50-1,500 mg
    Schisandra extract 300 mg  50-1,500 mg
    Ganoderma extract 150 mg  50-1,000 mg
    Maxcell™ 750 mg 100-2,500 mg
    L-arginine 200 mg  50-1,000 mg
  • The Schisandra extract contains schisandrins and the Ganoderma extract contains ganoderic acid and glucans. [0053]
    Formulation 3. “Anti-Stress” Formulation
    Tablet or capsule Daily Dosage
    Dose: 2-3 tablets per day Amount Effective Range
    Ziziphus jujuba Mill var. spinosa 200 mg  50-600 mg
    seed extract
    Gotu kola (Centella asiatica) 200 mg  50-600 mg
    whole plant extract
    Withania somnifera root extract 300 mg  50-600 mg
    Piper methylsticum rootstock extract 200 mg  50-500 mg
    Taurine
    200 mg   100-1,000 mg
    Maxcell™ 250 mg   100-2,500 mg
    • Example 7 Synergistic Effect of the Maxcell™ Vehicle on the Immune Stimulation Activity of the Super Immune Formulation
  • This experiment was performed as described in copending U.S. application Ser. No. 09/169,449, filed Oct. 9, 1998, entitled “Process for the Preparation of Immunomodulatory Polysaccharides from Aloe,” which is incorporated herein by reference in its entirety. Briefly, resident mouse peritoneal macrophages were isolated from ICR mice and plated at 200,000 cells per well in a 96-well plate. The cells were washed three times to remove non-adherent cells after a 2 hour incubation. The macrophages were then incubated with the Super Immune formulation, both with and without Maxcell™ overnight. The Maxcell™ vehicle was prepared as described in Example 1 and the Super Immune formulation was prepared as described in Example 6. Maxcell™ and the Super immune formulation were tested at 1.95 μg/mL, 3.91 μg/mL, 7.81 μg/mL, 15.63 μg/mL and 31.25 μg/mL. The TNF-α released into the media was determined by ELISA. Lipopolysaccharides (LPS) were used as a positive control. The results are set forth in FIG. 7. [0054]
    • Example 8 Improvement in Fatigue by the Bio Energy Formulation
  • ICR male mice, 8 weeks of age, were used for this experiment. The animals were fasted 18 hours prior to treatment with the Bio Energy formulation. Water was provided ab libitum. Positive control animals (8 mice) received one oral dose of 600 mg/kg glucose via gavage feeding. Negative control animals (8 mice) received one oral dose of 600 mg/kg saline via gavage feeding. Study animals (10 for each group) received 600 mg/mL of the BioEnergy formulation (prepared as described in Example 6) with MaxCell™, 600 mg/mL of the BioEnergy formulation without MaxCell™, and 134 mg/mL of MaxCell™ alone. [0055]
  • The animals received food and water ab libitum after being dosed. After 60 minutes, a 2 gram weight was glued to the end of the tails of the mice. Individual mice were placed into a tub (50 cm×30 cm×25 cm) of 20+/−0.5° C. water and allowed to swim until their heads went under water. The time of swim was recorded. The animals were then towel-dried and put into a warmed cage on top of a heating pad, until completely dry. The test results are depicted in FIG. 8. [0056]

Claims (17)

What is claimed is:
1. A biological vehicle for the delivery of biologically active agents, said vehicle comprising Aloe vera polysaccharide, piperine, cAMP, calcium phosphate and glycyrrhizin.
2. The vehicle of
claim 1
, wherein said polysaccharide, piperine, cAMP, calcium phosphate and glycyrrhizin are combined respectively in a weight-to-weight ratio that is substantially 2:1:0.005:10:6.
3. The vehicle of
claim 1
 wherein said Aloe vera polysaccharide is obtained from Aloe barbadensis.
4. The vehicle of
claim 1
 wherein said piperine is obtained from Piper longum or Piper negrum.
5. The vehicle of
claim 1
 wherein said cAMP is obtained from the fruit of Ziziphus jujuba.
6. The vehicle of
claim 1
 wherein said glycyrrhizin is obtained from Glycyrrgiza uralensis.
7. The vehicle of
claim 1
 wherein said glycyrrhizin is monoammonium substituted.
8. A pharmaceutical composition comprising the vehicle of
claim 1
 and at least one biologically active biological agents in a biologically effective amount.
9. The pharmaceutical composition of
claim 8
 in the form of a capsule or tablet.
10. The pharmaceutical composition of
claim 8
 wherein said additional compounds are selected from the group consisting of plant extracts or nutritional supplements.
11. The pharmaceutical compound of
claim 8
 wherein said nutritional supplements are selected from the group consisting of amino acids, water soluble vitamins, fat soluble vitamins, co-enzyme Q10, alpha ketoglutaric acid, minerals, antioxidants, or combinations of two or more of the above nutritional supplements.
12. The pharmaceutical compound of
claim 8
 wherein said plant extracts are selected from the group consisting of Panex Ginseng extract, Schisandra extract, Ganoderma extract, Ziziphus jujuba Mill var. spinosa seed extract, Gotu kola extract, Withania somnifera root extract, and Radix polygalae extract.
13. The compound of
claim 1
 further comprising L-tyrosine or a derivative thereof.
14. A method of using a composition comprising Aloe vera polysaccharide, piperine, cAMP, calcium phosphate and glycyrrhizin as a vehicle for the delivery of biologically active agents to a living organism, the method comprising administration of an effective amount of said biologically active agents in combination with said composition.
15. A biological vehicle for the delivery of one or more biologically active agents, said vehicle comprising at least one compound that enhances the bioavailability of said biological agents, at least one compound that enhances intracellular signaling processes, and at least one compound that enhances cell proliferation and cell survival.
16. The biological vehicle of
claim 15
 wherein said compound that enhances the bioavailability of said active agent acts by increasing the permeability of gastrointestinal epithelial cells to said active biological ingredient.
17. The biological vehicle of
claim 15
 wherein said compound that enhances the bioavailability of said active agent acts as a bioadhesive polymer, wherein said bioadhesive polymer binds to and coordinates said active biological agents; whereby said coordination increases the delivery of said active biological agents to the cell surface.
US09/301,892 1998-04-29 1999-04-29 Multicomponent biological vehicle Expired - Lifetime US6395311B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/301,892 US6395311B2 (en) 1998-04-29 1999-04-29 Multicomponent biological vehicle
US10/025,364 US20020071868A1 (en) 1998-04-29 2001-12-19 Multicomponent biological vehicle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8342098P 1998-04-29 1998-04-29
US09/301,892 US6395311B2 (en) 1998-04-29 1999-04-29 Multicomponent biological vehicle

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/025,364 Continuation US20020071868A1 (en) 1998-04-29 2001-12-19 Multicomponent biological vehicle

Publications (2)

Publication Number Publication Date
US20010006983A1 true US20010006983A1 (en) 2001-07-05
US6395311B2 US6395311B2 (en) 2002-05-28

Family

ID=26769282

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/301,892 Expired - Lifetime US6395311B2 (en) 1998-04-29 1999-04-29 Multicomponent biological vehicle
US10/025,364 Abandoned US20020071868A1 (en) 1998-04-29 2001-12-19 Multicomponent biological vehicle

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/025,364 Abandoned US20020071868A1 (en) 1998-04-29 2001-12-19 Multicomponent biological vehicle

Country Status (1)

Country Link
US (2) US6395311B2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075685A3 (en) * 2002-03-12 2003-11-06 Council Scient Ind Res Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
US20050272690A1 (en) * 2004-02-20 2005-12-08 Cremisi Henry D Compositions and methods for sleep regulation
US20080132611A1 (en) * 2006-03-24 2008-06-05 Century-Board Usa, Llc Polyurethane composite materials
WO2009103093A1 (en) * 2008-02-15 2009-08-20 Tshwane University Of Technology Use of aloe vera for increasing the bioavailability of poorly absorbable medicinal drugs
EP2221058A4 (en) * 2007-11-30 2010-12-01 Chi Yu Fen Antimelancholic medicine prepared with jujube camp materials
US20100310682A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions for treating anxiety
US20100310683A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions for treating depression and anxiety
EP2508082A1 (en) * 2011-04-04 2012-10-10 PM-International AG Food supplement preparation with amino acids and spice extract
CN110075069A (en) * 2009-05-06 2019-08-02 实验室护肤股份有限公司 Include activating agent-calcium phosphate granules compound dermal delivery composition and its application
US20240050451A1 (en) * 2020-09-25 2024-02-15 Mdm Enterprise Solutions Inc. Precision cannabinoid therapy formulations and methods of use

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821532B2 (en) * 2001-11-16 2004-11-23 Unitel Technologies, Inc. Methods and compositions for the treatment of benign prostatic hypertrophy
EP1323738A1 (en) * 2001-12-27 2003-07-02 2QR Research BV Negatively charged polysaccharide derivable form Aloe Vera
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
US7318374B2 (en) * 2003-01-21 2008-01-15 Victor Guerrero Wire cloth coffee filtering systems
US7461587B2 (en) * 2004-01-21 2008-12-09 Victor Guerrero Beverage container with wire cloth filter
US20050220846A1 (en) 2004-04-05 2005-10-06 Puntenney Steven B Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
CN100509006C (en) 2005-03-25 2009-07-08 北京欧纳尔生物工程技术有限公司 Pharmaceutical composition for treating depression and making method thereof
US20060257385A1 (en) * 2005-04-14 2006-11-16 Rogovin Jarrow L Dietary supplement formulations for improved delivery of coenzyme Q10 and methods of administration
EP1940455A4 (en) * 2005-04-14 2011-01-26 Jarrow Formulas Inc Dietary supplement formulations for improved delivery of coenzyme q10 and methods of administration
US20070036873A1 (en) * 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
TWI454261B (en) * 2007-01-09 2014-10-01 Unigen Inc Color ketones as therapeutic agents
MX354137B (en) 2011-01-19 2018-02-14 Laboratory Skin Care Inc Topical minocycline compositions and methods of using the same.
EP2968156A4 (en) 2013-03-15 2017-01-11 Laboratory Skin Care, Inc. Fine dry particulate resveratrol active agent compositions and topical formulations including the same
EP3110437B1 (en) 2014-02-12 2017-11-29 Omnigen Research, LLC Composition and method for promoting reduction of heat stress in animals
US10173375B2 (en) 2014-03-05 2019-01-08 Bacterin International, Inc. Shaped fiber-based products and method of manufacture thereof
CN104473258B (en) * 2014-12-10 2017-01-04 山东省食品发酵工业研究设计院 Fructus Jujubae vinegar beverage and the method extracting polysaccharide from winter jujub is produced from Fructus Jujubae Fructus Jujubae slag
US10821004B2 (en) 2015-06-30 2020-11-03 Bacterin Interational, Inc. Expandable bone grafts and methods of manufacture thereof
CN109568670B (en) * 2018-10-24 2021-05-07 温州医科大学 A kind of hydrogel for repairing endometrial injury and preparation method thereof
CN109529113B (en) * 2018-10-24 2021-03-02 温州医科大学 Filling material for low immunogenic bone defect and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214741A (en) * 1984-04-05 1985-10-28 Toyo Yakushiyoku Kogyo Kk Hypoglycemic agent
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
US5536506A (en) * 1995-02-24 1996-07-16 Sabinsa Corporation Use of piperine to increase the bioavailability of nutritional compounds
WO1996040182A1 (en) 1995-06-07 1996-12-19 Board Of Regents, The University Of Texas System Identification of a potent antioxidant from aloe barbadensis
JP2880434B2 (en) * 1995-09-05 1999-04-12 恒和化学工業株式会社 Gymnema Inodrum Roasted Tea
US5708038A (en) 1996-06-13 1998-01-13 Univera Pharmaceuticals, Inc. Method of using aloe vera as a biological vehicle

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075685A3 (en) * 2002-03-12 2003-11-06 Council Scient Ind Res Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
US20110081385A1 (en) * 2004-02-20 2011-04-07 Lifescape Biosciences Inc. Compositions and Methods for Sleep Regulation
US20050272690A1 (en) * 2004-02-20 2005-12-08 Cremisi Henry D Compositions and methods for sleep regulation
US7799817B2 (en) 2004-02-20 2010-09-21 Lifescape Biosciences Inc Compositions and methods for sleep regulation
US20080132611A1 (en) * 2006-03-24 2008-06-05 Century-Board Usa, Llc Polyurethane composite materials
AU2007362023B2 (en) * 2007-11-30 2012-04-19 Chi, Yu-Fen Antimelancholic medicine prepared with jujube camp materials
US20100310682A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions for treating anxiety
US20100310683A1 (en) * 2007-11-30 2010-12-09 Yu-Fen Chi Pharmaceutical compositions for treating depression and anxiety
EP2221058A4 (en) * 2007-11-30 2010-12-01 Chi Yu Fen Antimelancholic medicine prepared with jujube camp materials
WO2009103093A1 (en) * 2008-02-15 2009-08-20 Tshwane University Of Technology Use of aloe vera for increasing the bioavailability of poorly absorbable medicinal drugs
CN110075069A (en) * 2009-05-06 2019-08-02 实验室护肤股份有限公司 Include activating agent-calcium phosphate granules compound dermal delivery composition and its application
EP2508082A1 (en) * 2011-04-04 2012-10-10 PM-International AG Food supplement preparation with amino acids and spice extract
US20240050451A1 (en) * 2020-09-25 2024-02-15 Mdm Enterprise Solutions Inc. Precision cannabinoid therapy formulations and methods of use

Also Published As

Publication number Publication date
US20020071868A1 (en) 2002-06-13
US6395311B2 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
US6395311B2 (en) Multicomponent biological vehicle
KR101074158B1 (en) Composition comprising polysaccharide extracted from panax ginseng preventing and treating liver diseases
KR20120007275A (en) Immune Enhancing Composition Containing Plant Mixture Extract
KR101373245B1 (en) Composition for Preventing or Treating of Arthrits Comprising Herbal Extract
US8986756B2 (en) Composition comprising the extract of combined herbs for preventing and treating liver disease
Salama et al. Experimental and therapeutic trials of amygdalin
KR20180101460A (en) Uses of Sisotanke Tubulosa Extract and Isoquateroside in the Protection of Muscle
US20050214394A1 (en) Hippophae rhamnoides compositions for cancer therapy
CA2551787A1 (en) Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves and an anti-inflammatory agent
RU2358749C1 (en) Method of producing treated ginseng with increased amount of ginsenoside rg5
CN107551001B (en) A kind of traditional Chinese medicine compound for preventing and treating alcoholic liver injury and preparation method thereof
KR101445485B1 (en) A composition comprising the combined extract of Curcuma Longa L. and Nelumbo nucifera as an active ingredient showing anti-obesity and anti-hypercholesterolemia activity
US20150258158A1 (en) Compositions and methods for inhibition of triglyceride synthesis via synergistic combination of botanical formulations
WO2008069604A1 (en) Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease
RU2408383C1 (en) Composition with antineoplastic and adaptogenic activity (versions) and based drug (versions)
EP4043024B1 (en) Composition for preventing or treating parkinson's disease containing mixed herbal extract of genkwae flos, clematidis radix, and gastrodiae rhizoma
KR20200081553A (en) Composition for the prevention and improvement of Antitussive and Expectorant
KR100686260B1 (en) Liver function improvement and liver disease composition comprising jangguchae extract
KR101423875B1 (en) A composition comprising the complex extract for preventing or treating stroke and degenerative brain disease
KR100537954B1 (en) Composition activating and protecting brain fuctions
KR101796924B1 (en) Composition for improving hepatic function containing ginseng berry extracts
KR100826311B1 (en) Pharmaceutical composition containing peach extract as an active ingredient having inhibitory activity against liver and kidney toxicity induced by anticancer drugs
US20100074975A1 (en) Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract
CN112691170B (en) Traditional Chinese medicine composition for treating alopecia and application thereof
KR20180135845A (en) Pharmaceutical compositions for preventing or treating cancers comprising the nanoparticles of Dendropanax morbifera

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERA PHARMACEUTICALS, INC, COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JIA, QI;REEL/FRAME:010067/0696

Effective date: 19990602

AS Assignment

Owner name: UNIGEN PHARMACEUTICALS, INC., COLORADO

Free format text: CHANGE OF NAME;ASSIGNOR:UNIVERA PHARMACEUTICALS, INC.;REEL/FRAME:012775/0267

Effective date: 20020116

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: UNIGEN, INC., WASHINGTON

Free format text: CHANGE OF NAME;ASSIGNOR:UNIGEN PHARMACEUTICALS, INC.;REEL/FRAME:026385/0449

Effective date: 20100426

FPAY Fee payment

Year of fee payment: 12